Should minor stroke patients be thrombolyzed? A focused review and future directions

被引:66
作者
Yu, Amy Y. X. [1 ]
Hill, Michael D. [2 ,3 ,4 ,5 ]
Coutts, Shelagh B. [1 ,2 ,5 ]
机构
[1] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[2] Univ Calgary, Dept Radiol, Calgary, AB, Canada
[3] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
[4] Univ Calgary, Dept Med, Calgary, AB, Canada
[5] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
关键词
acute stroke therapy; CT scan; ischemic stroke; minor stroke; TIA; tPA; TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; INTRAVENOUS THROMBOLYSIS; COGNITIVE IMPAIRMENT; MILD SYMPTOMS; SCALE SCORES; DOUBLE-BLIND; ALTEPLASE;
D O I
10.1111/ijs.12426
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Stroke is a leading cause of morbidity and mortality worldwide. Up to 80% of ischemic stroke patients may initially present with minor symptoms. Minor stroke and transient ischemic attack patients are typically treated conservatively with antiplatelet agents and general vascular prevention strategies. Yet a high proportion develop recurrent stroke or progression of stroke and up to one in four of these patients are disabled or dead at follow-up. Minor or rapidly improving symptoms are the top reasons for withholding thrombolytic therapy to time-eligible stroke patients as they are believed to be too good to treat'. The benefits and risks of treating mild ischemic strokes are still unclear. The increasing use of computed tomography angiography and its ability to identify both proximal and distal intracranial occlusions may change this equation. In this review, we discuss the diagnosis and prognosis of mild strokes, the role of neurovascular imaging in treatment decision making, experience with thrombolysis in this patient population, and propose directions for future studies.
引用
收藏
页码:292 / 297
页数:6
相关论文
共 47 条
  • [1] [Anonymous], 2014, LANCET
  • [2] Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction
    Armstrong, Paul W.
    Gershlick, Anthony H.
    Goldstein, Patrick
    Wilcox, Robert
    Danays, Thierry
    Lambert, Yves
    Sulimov, Vitaly
    Rosell Ortiz, Fernando
    Ostojic, Miodrag
    Welsh, Robert C.
    Carvalho, Antonio C.
    Nanas, John
    Arntz, Hans-Richard
    Halvorsen, Sigrun
    Huber, Kurt
    Grajek, Stefan
    Fresco, Claudio
    Bluhmki, Erich
    Regelin, Anne
    Vandenberghe, Katleen
    Bogaerts, Kris
    Van de Werf, Frans
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (15) : 1379 - 1387
  • [3] Routine CT Angiography in Acute Stroke Does Not Delay Thrombolytic Therapy
    Bal, Simerpreet
    Menon, Bijoy K.
    Demchuk, Andrew M.
    Hill, Michael D.
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2012, 39 (04) : 499 - 501
  • [4] Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
    Barber, PA
    Zhang, J
    Demchuk, AM
    Hill, MD
    Buchan, AM
    [J]. NEUROLOGY, 2001, 56 (08) : 1015 - 1020
  • [5] NEW VARIANT OF HUMAN TISSUE-PLASMINOGEN ACTIVATOR (TPA) WITH ENHANCED EFFICACY AND LOWER INCIDENCE OF BLEEDING COMPARED WITH RECOMBINANT HUMAN TPA
    BENEDICT, CR
    REFINO, CJ
    KEYT, BA
    PAKALA, R
    PAONI, NF
    THOMAS, GR
    BENNETT, WF
    [J]. CIRCULATION, 1995, 92 (10) : 3032 - 3040
  • [6] Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction
    Binbrek, AS
    Rao, NS
    Neimane, D
    Hatou, E
    Abdulali, S
    Sobel, BE
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (12) : 1465 - 1468
  • [7] Recombinant tissue plasminogen activator for minor strokes: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Experience
    Broderick, JP
    Brott, T
    DeGraba, T
    Fagan, SC
    Frankel, MR
    Grotta, JC
    Haley, EC
    Hamilton, S
    Kwiatkowski, T
    Levine, SR
    Lewandowski, CA
    Lin, Y
    Libman, R
    Lu, M
    Lyden, P
    Marler, JR
    Morgenstern, L
    Patel, S
    Sanders, C
    Tilley, BC
    [J]. ANNALS OF EMERGENCY MEDICINE, 2005, 46 (03) : 243 - 252
  • [8] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial
    Clark, WM
    Wissman, S
    Albers, GW
    Jhamandas, JH
    Madden, KP
    Hamilton, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2019 - 2026
  • [9] The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) - Results of a double-blind, placebo-controlled, multicenter study
    Clark, WM
    Albers, GW
    Madden, KP
    Hamilton, S
    [J]. STROKE, 2000, 31 (04) : 811 - 816
  • [10] Recurrent events in transient ischemic attack and minor stroke - What events are happening and to which patients?
    Coutts, Shelagh B.
    Hill, Michael D.
    Campos, Cynthia R.
    Choi, Young B.
    Subramaniam, Suresh
    Kosior, Jayme C.
    Demchuk, Andrew M.
    [J]. STROKE, 2008, 39 (09) : 2461 - 2466